Ocrelizumab: A Review in Multiple Sclerosis.

ABSTRACT: Ocrelizumab (Ocrevus^®) is an intravenously administered, humanized anti-CD20 monoclonal antibody approved for the treatment of adults with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The efficacy of ocrelizumab in reducing relapse rates and disease activity in patients with RMS was demonstrated in pivotal trials (versus interferon β-1a) and supporting single-arm studies in specific subpopulations. In patients with PPMS, ocrelizumab reduced measures of clinical and MRI progression relative to placebo. Clinical benefits were maintained over ≥ 7.5 study years of treatment. Ocrelizumab was generally well tolerated and no new safety signals have emerged with long-term use. Extensive (albeit short-term) real-world data pertaining to oc

SUBMITTER: Lamb YN 

PROVIDER: S-EPMC8862399 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature